Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.50
-0.02-1.32%
At close: -
$1.50
0.000.00%
After Hours: May 16, 6:39 PM EDT
Comments
Loading...
Tango Therapeutics Analyst Ratings and Price Targets | NASDAQ:TNGX | Benzinga
Tango Therapeutics Inc has a consensus price target of $13.14 based on the ratings of 8 analysts. The high is $19 issued by Jefferies on July 17, 2024. The low is $8 issued by B. Riley Securities on November 11, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co. on April 14, 2025, November 11, 2024, and November 8, 2024, respectively. With an average price target of $11.33 between HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co., there's an implied 655.56% upside for Tango Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B. Riley Securities
Guggenheim
Wedbush
Jefferies
1calculated from analyst ratings
Analyst Ratings for Tango Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/14/2025 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Reiterates | Overweight → Overweight | Get Alert |
| 11/11/2024 | Buy Now | 433.33% | B. Riley Securities | Yuan Zhi29% | $16 → $8 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 433.33% | Guggenheim | Charles Zhu59% | $18 → $8 | Maintains | Buy | Get Alert |
| 10/28/2024 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 766.67% | Wedbush | Robert Driscoll43% | $11 → $13 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 1166.67% | Jefferies | Maury Raycroft31% | → $19 | Initiates | → Buy | Get Alert |
| 07/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Reiterates | → Overweight | Get Alert |
| 07/09/2024 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 766.67% | HC Wainwright & Co. | Robert Burns42% | $16 → $13 | Maintains | Buy | Get Alert |
| 05/24/2024 | Buy Now | 833.33% | Guggenheim | Charles Zhu59% | $16 → $14 | Maintains | Buy | Get Alert |
| 05/24/2024 | Buy Now | 766.67% | Barclays | Peter Lawson42% | $18 → $13 | Maintains | Overweight | Get Alert |
| 05/23/2024 | Buy Now | 633.33% | Wedbush | Robert Driscoll43% | $18 → $11 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 1033.33% | HC Wainwright & Co. | Robert Burns42% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Initiates | → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 1033.33% | HC Wainwright & Co. | Robert Burns42% | $16 → $17 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 1100% | Piper Sandler | Joseph Catanzaro44% | → $18 | Initiates | → Overweight | Get Alert |
| 12/08/2023 | Buy Now | 966.67% | B. Riley Securities | Yuan Zhi29% | → $16 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 966.67% | HC Wainwright & Co. | Robert Burns42% | $11 → $16 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 633.33% | HC Wainwright & Co. | Robert Burns42% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 1100% | Wedbush | Robert Driscoll43% | → $18 | Reiterates | → Outperform | Get Alert |
| 03/28/2023 | Buy Now | 633.33% | HC Wainwright & Co. | Robert Burns42% | $10 → $11 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 566.67% | HC Wainwright & Co. | Robert Burns42% | → $10 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Tango Therapeutics (TNGX) stock?
The latest price target for Tango Therapeutics (NASDAQ:TNGX) was reported by HC Wainwright & Co. on April 14, 2025. The analyst firm set a price target for $13.00 expecting TNGX to rise to within 12 months (a possible 766.67% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tango Therapeutics (TNGX)?
The latest analyst rating for Tango Therapeutics (NASDAQ:TNGX) was provided by HC Wainwright & Co., and Tango Therapeutics reiterated their buy rating.
When was the last upgrade for Tango Therapeutics (TNGX)?
There is no last upgrade for Tango Therapeutics
When was the last downgrade for Tango Therapeutics (TNGX)?
There is no last downgrade for Tango Therapeutics.
When is the next analyst rating going to be posted or updated for Tango Therapeutics (TNGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tango Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tango Therapeutics was filed on April 14, 2025 so you should expect the next rating to be made available sometime around April 14, 2026.
Is the Analyst Rating Tango Therapeutics (TNGX) correct?
While ratings are subjective and will change, the latest Tango Therapeutics (TNGX) rating was a reiterated with a price target of $13.00 to $13.00. The current price Tango Therapeutics (TNGX) is trading at is $1.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
